“Operation Warp Speed” Partners with Moderna for 100 million Covid-19 Vaccines

Reading time: minutes

Share this

https://“Operation%20Warp%20Speed”%20Partners%20with%20Moderna%20for%20100%20million%20Covid-19%20Vaccines

Chemical Safety Software is proud to announce that their client, Moderna, Inc. has partnered with the US Government’s Operation Warp Speed (OWS) to produce 100 million Covid-19 vaccine doses by the end of the year.

Moderna Inc. (MRNA) said its experimental coronavirus vaccine successfully induced immune responses in people aged 56 years and older that were comparable to those seen in younger adults in a small study, a promising sign for a vulnerable age group.

In a press release, Fox Business claimed that the OWS-Moderna deal is valued at approximately 1.5 billion dollars and will guarantee that the vaccine is provided cost-free to Americans, although some may incur costs for the administering of the vaccine.  The deal also gives the government an option on an additional 400 million doses.

According to HHS Secretary Alex Azar, Operation Warp Speed (OWS) is a historic effort to bring vaccines, therapeutics, and diagnostics to the American people in record time.  The objective of OWS, is to compress and wring out every inefficiency in the process, take out every unused day, and at the same time, scale-up manufacturing so that as we get vaccines that work, we will be able to distribute them right away.

OWS is a partnership among components of the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD). OWS engages with private firms and other federal agencies, including the Department of Agriculture, the Department of Energy, and the Department of Veterans Affairs. It will coordinate existing HHS-wide efforts, including the NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, and work by BARDA.

See also